PNEUMONIA DUE TO MYCOPLASMA PNEUMONIAE; A literature report has been received. The report concerns a child of unknown gender of Unknown ethnic origin, enrolled in a study.    for the 2020-21 season, the flu vaccination had been extended to all children. A quadrivalent live attenuated influenza vaccine (qLAIV) was administered to children aged 2-17 years for the first time. Number and severity of adverse reactions to (Fluenz Tetra) and the factors influencing them were registered, uniformity of access to care was evaluated and degree of satisfaction with the vaccination of both parents and health care providers was assessed, in order to improve the 2021-22 vaccination program.     On vaccination day, a questionnaire was given out to collect information about the children and their parents. Between 1 and 3 months later, the parents were contacted to record any adverse reactions following (Fluenz Tetra) and rate the degree of satisfaction.     This observational study was conducted in Hospital together with the Health facility during the 2020-21 influenza vaccination campaign. In the six vaccination centres in the city a total of 9292 children received the (Fluenz Tetra) vaccine: 7675 in the 2 to 6 age group and 1617 in the 7 to 17 one.    A data of 3226 children was received from 2152 families. Adverse events were reported in 24.8 percent of children: 80.6 percent mild, 18.1 percent moderate and 1.3 percent significant. The most common were rhinitis (52.5 percent) and fever (24.4 percent). This case is for one of the patients who experienced Mycoplasma Pneumoniae after vaccination.    No medical history was reported.     No concomitant products were reported.    The patient received Fluenz Tetra (influenza vaccine live reassort 4v), via nasal route, for vaccination on an unknown date.     No malfunction has been reported for FLUENZ TETRA.    On an unknown date, 3 days after starting treatment with Fluenz Tetra, the patient experienced pneumonia due to mycoplasma pneumoniae (preferred term: Pneumonia mycoplasmal).     It was unknown if any action was taken with Fluenz Tetra (influenza vaccine live reassort 4v).     The outcome of the event was unknown.    The event was considered serious (hospitalised).     The reporter considered the following event related to treatment with Fluenz Tetra (influenza vaccine live reassort 4v): pneumonia due to mycoplasma pneumoniae.   The company physician considered the following event related to treatment with Fluenz Tetra (influenza vaccine live reassort 4v): pneumonia due to mycoplasma pneumoniae.  Device Information:     Combination Product Report: Yes    Product As Reported: FLUENZ TETRA  Common Device Name: Nasal Spray  Procode: CCQ  Product Role: Suspect     Follow-up of insignificant information received by AstraZeneca on 31-Jan-2022: reference reporter and ID was added, narrative was edited.; Sender's Comments: Pneumonia mycoplasmal not listed in the core company data sheet of Q/LAIV. Due to limited information on patient demographics, relevant medical history, previous medication history, concomitant medications, suspect drug start date, event onset date, circumstances leading to event, risk factors (smoking, alcohol, obesity), treatment details, detailed etiological, diagnostic workup as clinical examination, complete blood work (including inflammatory markers), imaging studies, the evaluation did not find evidence to suggest a causal relationship of event and suspect drug.